C12Y 204/01149
N-acetyllactosaminide beta-1,3-n-acetylglucosaminyltransferase
Official title: N-Acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase (2.4.1.149)
C12Y204/01149 (N-acetyllactosaminide beta-1,3-n-acetylglucosaminyltransferase) appears on 8 US grants and 14 published applications in this corpus.
Search patents in C12Y- Granted patents
- 8
- Published applications
- 14
- Assignees
- 8
- Inventors
- 31
- Latest grant
- 17 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2017 | 0 | 2 |
| 2018 | 0 | 1 |
| 2019 | 0 | 2 |
| 2020 | 1 | 1 |
| 2021 | 1 | 0 |
| 2022 | 3 | 3 |
| 2023 | 1 | 0 |
| 2024 | 1 | 3 |
| 2025 | 0 | 1 |
| 2026 | 1 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Genetically engineered strains with reduced byproduct formation17 Feb 2026US 12,553,071 B2Dsm IP Assets B.V.
- Oligosaccharide production12 Mar 2024US 11,926,858 B2Glycom A/S
- Alpha (1,2) fucosyltransferase syngenes for use in the production of fucosylated oligosaccharides9 May 2023US 11,643,675 B2Glycosyn LLC
- Separation of oligosaccharides from fermentation broth26 Apr 2022US 11,312,741 B2Glycom A/S
- Oligosaccharide production5 Apr 2022US 11,293,042 B2Glycom A/S
- Compositions and methods relating to age-related, neurological, and vascular disease conditions20 Aug 2026US 2026/0241037 A1The Board of Trustees of the Leland Stanford Junior University
- Hmo producing microorganism with increased robustness towards glucose gradients18 Sep 2025US 2025/0290078 A1
- Genetically engineered strains with reduced byproduct formation12 Dec 2024US 2024/0409972 A1Dsm IP Assets B.V.
- Methods of producing human milk oligosaccharides and compositions thereof21 Nov 2024US 2024/0384315 A1Amyris, Inc.
- Novel targets for enhancing anti-tumor immunity8 Aug 2024US 2024/0261333 A1Massachusetts Institute of Technology
Most cited
By later US patents